Treatment options for

metastatic urothelial carcinoma:

Challenge the expert

Axel MerseburgerEnrique Grande and María-José Juan-Fita are faced with a challenge to find the best treatment approach for different metastatic urothelial carcinoma (mUC) case studies. They might not agree, but each one will have an opportunity to challenge the other’s viewpoint to create a lively debate.

Watch these two video discussions to expand your knowledge of first- and subsequent-line immunotherapy treatment options and see how the experts work together to find possible solutions.

About this activity

Learning objectives

After studying the content, participants will be able to:

  • discuss current and emerging immune-based regimens for mUC and the clinical data supporting them
  • debate how to best integrate and sequence new immunotherapy options in the landscape of mUC to achieve optimal clinical outcomes
  • evaluate the importance of predictive factors to enhance patient selection and move to personalized care

This independent programme is supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

All content has been developed independently by Springer Healthcare IME, in conjunction with an expert Faculty.

Login to access this activity

  • This field is for validation purposes and should be left unchanged.

Module Content